InspireMD, Inc. (NYSEMKT:NSPR) Files An 8-K Other Events
Item 8.01 Other Events.
On March 20, 2017, InspireMD, Inc. (the Company) announced
signing a distribution agreement for CGuard EPS, covering the
Russian Federation. A copy of the press release is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is hereby
incorporated by reference herein.
On March 21, 2017, the Company announced signing a distribution
agreement for CGuard EPS with a distribution partner in Hong
Kong. A copy of the press release is attached as Exhibit 99.2 to
this Current Report on Form 8-K and is hereby incorporated by
reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description | |
| 99.1 | Press release dated March 20, 2017 | |
| 99.2 | Press release dated March 21, 2017 |
About InspireMD, Inc. (NYSEMKT:NSPR)
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device. InspireMD, Inc. (NYSEMKT:NSPR) Recent Trading Information
InspireMD, Inc. (NYSEMKT:NSPR) closed its last trading session down -0.040 at 0.940 with 598,702 shares trading hands.
